Background-Estimates of the heritability of plasma fibrinogen concentration, an established predictor of cardiovascular disease, range from 34% to 50%. Genetic variants so far identified by genome-wide association studies explain only a small proportion (<2%) of its variation. Methods and Results-We conducted a meta-analysis of 28 genome-wide association studies including >90 000 subjects of European ancestry, the first genome-wide association meta-analysis of fibrinogen levels in 7 studies in blacks totaling 8289 samples, and a genome-wide association study in Hispanics totaling 1366 samples. Evaluation for association of singlenucleotide polymorphisms with clinical outcomes included a total of 40 695 cases and 85 582 controls for coronary artery disease, 4752 cases and 24 030 controls for stroke, and 3208 cases and 46 167 controls for venous thromboembolism.
F ibrinogen plays a major role in wound healing and thrombosis. Circulating levels of fibrinogen are upregulated in inflammatory conditions, consequently serving as an important marker of inflammation. Fibrinogen is a well-established predictor of cardiovascular disease outcomes such as myocardial infarction, 1,2 stroke, 3 and venous thromboembolism (VTE). 4, 5 
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It is estimated that 34% (extended pedigrees study) to 44% (twins study) of the interindividual variation in fibrinogen levels is heritable, 6, 7 indicating a substantial influence of genetics. Two recent meta-analyses of genome-wide association (GWA) studies, conducted in cohorts of European ancestry, identified several genetic variants affecting fibrinogen levels. 8, 9 These variants account only for a small proportion (<2%) of plasma fibrinogen variation, suggesting that additional genetic variants with more modest effects may remain to be detected.
There is now increasing evidence that a substantial proportion of consequential genetic variation for many phenotypes is tagged by common single-nucleotide polymorphisms (SNPs), 10 although most of these SNPs cannot pass the restrictive genome-wide significance level of P<5×10 −8 in a typical association study. To overcome this limitation, increased sample sizes are needed. We conducted a large meta-analysis of 28 GWA studies including >90 000 individuals of European ancestry, a 4-fold increase in sample size compared with previous meta-analyses. 8, 9 We included data from an additional 8423 samples from the first GWA studies of blacks and 1447 Hispanic individuals to also explore whether ethnic differences exist in the genetic regulation of plasma fibrinogen concentration. To further elucidate possible biological mechanisms underlying fibrinogen regulation, we examined genome-wide significant loci in relation to expression levels of nearby genes and in gene pathway analyses. Finally, we examined whether fibrinogen-related genes affect risk of coronary artery disease (CAD), stroke, and VTE. [11] [12] [13] [14] [15] [16] 
Methods

Cohorts and Plasma Fibrinogen Measurements
Twenty-eight studies contributed to the discovery GWA study metaanalysis of European-ancestry individuals. Characteristics of all participating studies are provided in the Methods section and Table I in the online-only Data Supplement. In 7 cohorts with 33 745 individuals, plasma fibrinogen concentration was measured by an immunonephelometric method. 17 For the other 21 European-ancestry cohorts (57 578 individuals), plasma fibrinogen levels were determined by a functional method (based on the Clauss method). 18 Seven black cohorts with GWA data, including a total of 8423 individuals (5937 with Clauss and 2486 with immunonephelometric measures), and 1 cohort of 1447 Hispanics with immunonephelometric fibrinogen measures were also analyzed (Methods section and Table II in the online-only Data Supplement). Exclusion criteria applied in individual cohorts are provided in the Methods section in the online-only Data Supplement.
All studies were approved by the relevant research ethics committees.
Genotyping, Quality Control of Genotype Data, and Imputation
Commercial arrays were used for genome-wide genotyping in all cohorts, and quality-control filtering of SNP genotype data was generally performed in individual cohorts by call rate, minor allele frequency, and deviation from Hardy-Weinberg equilibrium (Methods section and Tables III and IV in the online-only Data Supplement). Approximately 2.5 million autosomal SNPs were imputed cohorts with the HapMap II white (CEU; Center d'Etude du Polymorphisme Humain) sample as reference panel for the European-ancestry cohorts, a combined CEU+YRI reference panel for the black cohorts, and a combined CEU+YRI+CHB+JPT reference panel for the Hispanic sample (CEU, European Ancestry from Centre d'Etude du Polymorphisme Humain; YRI, Yoruba in Ibadan, Nigeria; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan). MACH or IMPUTE software [19] [20] [21] was used in the imputation (Tables III and IV in 
Meta-Analysis of GWA Studies
Values of plasma fibrinogen concentration were natural logarithmtransformed before analysis. Association analyses were conducted in each cohort of measured and imputed autosomal SNP allele dosage with fibrinogen values with a linear regression model assuming additive genetic effects adjusted for age and sex. Additional adjustments for principal components or multidimensional scaling, country, or center were made when necessary by individual cohorts to account for population stratification (see Methods in the online-only Data Supplement). Relatedness was accounted for in family studies by applying linear mixed-effect models. Genotype-phenotype association results from the 28 cohorts were then meta-analyzed by use of an inverse-variance model with fixed effects in METAL (http://www. sph.umich.edu/csg/abecasis/Metal/index.html). 22 To identify additional independent association signals in the genome-wide significant loci, conditional GWA analysis was performed as described in the Methods in the online-only Data Supplement. Overall, we selected for further analysis only SNPs from genome-wide significantly associated loci, including the lead SNP for each locus in the initial meta-analysis, along with 1 additional lead SNP representing a new clear signal identified in the conditional analysis.
To identify genes that regulate fibrinogen levels in other ethnic groups, we conducted a separate GWA meta-analysis using 7 separate GWA scans in blacks totaling 8289 samples and a single GWA analysis in a cohort of Hispanics totaling 1366 samples.
The threshold of genome-wide significance was set at P=5.0×10 −8 for the primary analyses of GWA with plasma fibrinogen levels and their heterogeneity measures, as well as for the conditional metaanalysis. We used Bonferroni correction for the exploration of the 24 lead-SNPs in the black and Hispanic samples and for the lookups in clinical outcomes (P<0.002).
Genetic Risk Score
A genetic risk score was computed using data from 88 251 Europeanancestry individuals to model the increase in fibrinogen levels according to the number of fibrinogen-raising alleles for each lead SNP. Methods are further described in Methods in the online-only Data Supplement.
Multivariable-Adjusted Model
We reanalyzed the association with plasma fibrinogen concentration of the lead SNPs using a linear model with further adjustment for body mass index and smoking, in addition to sex and age and the extra covariates used in each cohort in the discovery analyses. Association results from all cohorts were then meta-analyzed with the inverse-variance-weighted fixed-effects meta-analysis implemented in METAL.
Pathway Analyses
MAGENTA and GRAIL 23, 24 were used to assess putative relationships between the lead SNPs and to infer genes and pathways underlying SNP associations with plasma fibrinogen levels. MAGENTA version 2 analysis was performed as described, 24 including gene sets from Gene Ontology, KEGG, PANTHER, and Ingenuity downloaded in June 2011 (http://www.broadinstitute.org/mpg/magenta/). Gene-set statistics were determined for an empirically derived 95th percentile threshold of gene-wide adjusted P values. Only gene sets meeting a false discovery rate <0.05 were considered for further inspection. Candidate SNPs were identified in the MAGENTA analysis as SNPs with nominal locus-wide corrected P values (corrected P<0.05) mapping to genes in gene sets that met the false discovery rate of <0.05. GRAIL analysis was performed as described (http://www.broadinstitute.org/mpg/grail/) using the pair-wise similarity metric compiled from the literature in December 2006 to limit bias, as recommended. 25 
Association With Gene Expression in Human Liver
The lead SNPs and their perfect proxies (r 2 =1) were further analyzed with respect to association with expression levels of nearby genes (located within ±200 kb of the SNP).
Global gene expression data from human liver were obtained from the Advanced Study of Aortic Pathology (ASAP). 26 Details of the ASAP biobank and the methods for gene expression analysis and genotyping are provided in the Methods section in the online-only Data Supplement. Further queries were made against significant results from 4 other liver eQTL analyses with methods that were published previously. [27] [28] [29] [30] 
Associations With Clinical Outcomes
We examined associations of the 24 lead SNPs with prevalent CAD, stroke, and VTE. Genotype-CAD association results for the selected SNPs were obtained from the Coronary Artery Disease Genome-wide Replication and Meta-analysis (CARDIoGRAM) and Europe South Asia Coronary Artery Disease Genetics (C4D) consortia, including a total of 40 695 CAD cases and 85 582 controls. Lead SNP associations with stroke were explored in data generated from 4 large cohorts composing the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, including 1544 incident strokes (1164 ischemic strokes) developed over an average follow-up of 11 years, and 18 058 controls and in data generated from 4 cohorts making up the Welcome Trust Case Control Consortium (WTCCC), including 3548 cases with ischemic stroke and 5972 controls. The SNP genotype-VTE association results were generated in 3208 VTE cases and 46 167 controls from the French Marseille Thrombosis Association Study (MARTHA) and the CHARGE studies. Definitions of the disease phenotypes adopted in each individual study are detailed elsewhere. [11] [12] [13] [14] [15] 31 Each of the 24 fibrinogen-associated SNPs was tested for association with each of the clinical outcomes by logistic regression with adjustment for age and sex. The log odds ratios and their standard errors for each SNP were standardized for direction and magnitude to correspond to the change in allele dosage that accounted for a 3.1% relative increase in circulating fibrinogen level (fibrinogen effect associated with the FGB variant rs1800789). These harmonized effect estimates were then pooled by fixed-effects (inverse-varianceweighted) meta-analysis (stroke and VTE) or by random-effects meta-analysis (for CAD owing to significant heterogeneity in both the direction and magnitude of the harmonized log odds ratios).
Results
Meta-Analysis in European-Ancestry Samples
Meta-analysis was performed for 2 515 567 SNPs on individual GWA study results generated in 28 European-ancestry cohorts including a total of 91 323 individuals. A total of 985 SNPs, located in 23 chromosomal loci, passed the genome-wide significance threshold of P=5.0×10 −8 (Figure 1 ). Among the 23 loci (designated according to nearest gene), 8 (IL6R, NLRP3, IL1RN, CPS1, PCCB, FGB, IRF1, and CD300LF) represent replications of previously identified fibrinogen-associated loci, and 15 are novel associations (JMJD1C, LEPR, PSMG1, CHD9, SPPL2A, PLEC1, FARP2, MS4A6A, TOMM7/IL6, ACTN1, HGFAC, IL1R1, DIP2B, and SHANK3/CPT1B). More information about these genes is provided in Table V in the online-only Data Supplement. Further information about the lead SNPs and their association with fibrinogen levels is given in Table 1 .
To search for further independent association signals within the 23 loci, we repeated the individual GWA analyses, conditioning on the 23 lead SNPs. This analysis revealed 2 genome-wide significant SNPs located in the FGA gene (rs2070016; P=3.9×10 −8 ) and on chromosome 5 (rs11242111; P=1.60×10 −21 ; Figure I in the online-only Data Supplement). Accordingly, rs11242111 was added to the list of independent lead SNPs selected for further analyses (Table 1 ). rs2070016, in FGA, showed evidence of correlation with the lead SNP rs1800789 in FGB (r 2 =0.364 according to 1000 Genomes Map Pilot 1); hence, we did not select this SNP for further analyses. After adjustment for the number of tests, none of the 24 lead SNPs showed significant heterogeneity across Europeanancestry cohorts. Regional association plots for the 24 loci are shown in Figure II in the online-only Data Supplement.
Further adjustment for body mass index and smoking, which together explained 5.3% of the variation in plasma fibrinogen level among 81 511 individuals from the Europeanancestry meta-analysis, resulted in stronger associations for most of the lead SNPs but no new discoveries (Table 1) .
Meta-Analysis and Validation of European-Ancestry Loci in the Black and Hispanic Samples
The Manhattan and QQ plots (λ=1.012) reporting the results for the black samples are shown in Figure III in the onlineonly Data Supplement. Only the FGA/FGB/FGG locus on chromosome 4 reached genome-wide significance in the black cohort meta-analysis, with the most strongly associated SNP being rs4463047 (P=4.63×10 −10 ) at 12 790 bp from rs1800789 (P=4.02×10 −7 ) . No single SNP attained genome-wide significance in the Hispanic samples ( Figure III in the online-only Data Supplement).
We tested the association of the 24 European-ancestry lead SNPs in the black cohort meta-analysis (Table VI in the online-only Data Supplement). After correction for 24 statistical tests (P value threshold <0.002), only the 2 lead SNPs, rs1800798 (FGB) and rs6734238 (ILRN), passed the significant threshold. However, 5 other lead SNPs, located in the IRF1, IL6R, CHD9, JMJD1C, and MS4A6A loci, were associated at P<0.05, with consistent directions of effect in both populations ( Table VII in the online-only Data Supplement) . Furthermore, at 20 of the 24 lead SNPs, the direction of the β estimate was the same in the European and black samples (P=0.00077, sign test).
In the Hispanic samples, 3 European-ancestry lead SNPs, in FGB (rs1800798), IL6R (rs6734238), and CHD9 (rs7204230), passed the significance threshold (24 SNPs; P<0.002) for association, and 3 additional lead SNPs were associated at a nominally significant threshold of P<0.05, with consistent directions of effect in both populations (Table VI in the onlineonly Data Supplement). In addition, the direction of the β estimate at 20 of the 24 lead SNPs was the same in the European and Hispanic samples (P=0.00077, sign test). Figure 2 presents the average fibrinogen values across categories of the genetic risk score. The mean percentage of residual variance (after adjustment for age and sex) explained by 24 lead SNPs was 3.7% in all European-ancestry cohorts (range, 1.4%-7.6% in individual cohorts). The heritability of plasma fibrinogen concentration estimated from the family cohorts within this study (Netherlands Twin Registry, CROATIA-Vis, CROATIA-Korcula, ORCADES, FHS, and SardiNIA) ranged from 15% to 51% (mean±SD, 31±15%; see Results in the online-only Data Supplement). The proportion of variance in fibrinogen levels explained by common SNPs (minor allele frequency >0.01) was calculated in 1 of our participant cohorts (WGHS, n=21,336) using the method proposed by Yang et al. 10 Results showed that 16% (SE=0.017) of the variance in fibrinogen levels was explained by common SNPs. Finally, the genetic risk score was strongly associated with levels of fibrinogen in the combined black cohorts (P=1.5×10 −8 ) and the Hispanic cohort (P=3.8×10 −15 ).
Table 1. Details of the 24 Lead SNPs and Association β and P Values for the Original Meta-Analysis Performed With the European-Ancestry Cohorts (Adjusted for Age and Sex)
Together With the Corresponding Values Obtained in the Same Cohorts With Further Adjustments for BMI and Smoking
Genetic Risk Score and Proportion of Variance Explained
Pathway and Expression QTL Analyses
We performed additional in silico pathway analyses using GRAIL and MAGENTA (Table VIII in the online-only Data Supplement). The GRAIL results identified 6 SNPs (rs6734238, rs12712127, rs8192284, rs10157379, rs1938492, and rs6831256) that were located within or near genes (IL1RN, IL1R1, IL6R, NLRP3, LEPR, and LRPAP1) with significantly related function among all of the genes in the vicinity of the 24 lead SNPs, suggesting that these genes should be prioritized as the most plausible functional candidate genes within the associated loci. Gene-set enrichment analysis using MAGENTA (based on the whole genome-wide genetic data set) identified several gene sets and pathways that were enriched in the analysis ( Table IX in the online-only Data Supplement). Apart from the 3 structural genes, the most represented pathways were related to inflammation (acute-phase response, interleukin signaling), adipocytokine signaling, and thyrotrophin-releasing hormone signaling. According to these results, several genes (LEPR, IL6R, IL1R, IL1F10/IL1F5/IL1F8/IL1RN, FGA/FGB, ACTN1, and CPT1B) were prioritized as plausible candidate genes within our 23 genomic regions. A comprehensive SNP list, which includes both the 24 lead SNPs and the SNPs selected by either GRAIL or MAGENTA on the whole genome-wide genetic data set, is given in Table IX in the online-only Data Supplement.
We then interrogated the 24 lead SNPs and their perfect proxies with respect to their associations with expression levels of nearby genes (located within ±200 kb of the lead SNP) in 5 human liver databases. Expression levels of LEPR, PCCB, MSL2L1, NGFRAP1, FGB, and TOMM7 were significantly associated with allelic differences in 1 of the 24 lead SNPs (results are shown in Table VIII in the online-only Data Supplement). Finally, to assess the functional role of SNPs in fibrinogen genes, we also studied the eQTL associations of all SNPs within 100 kb of the fibrinogen gene cluster. The highest association with expression of fibrinogen transcripts within the fibrinogen cluster was found for SNP rs4220 (P=1.38×10 −20 ), causing a missense mutation in the FGB gene. All positive associations with fibrinogen transcripts are shown in Table X in the online-only Data Supplement.
Associations With Clinical Outcomes
After correction for multiple testing (P<0.002 threshold), rs4129267 located in the IL6R locus, rs6734238 in the IL1F10/ IL1RN locus, and rs1154988 in the PCCB locus were found to be significantly associated with CAD; however, the directions of the effects on CAD and fibrinogen levels were consistent only for rs4129267 in the IL6R locus. The pooled association for the 24 lead SNPs with CAD was not significant (odds ratio, 1.00; 95% confidence interval, 0.97-1.03). None of the fibrinogenassociated lead SNPs were significantly associated with stroke or VTE after correction for multiple testing. The pooled results were suggestive for stroke (odds ratio, 1.03; 95% confidence interval, 1.00-1.07) but not for VTE (odds ratio, 0.96; 95% confidence interval, 0.92-1.01; Table 2 ). Additional results from the WTCCC stroke consortium, generated according to clinical subphenotypes, are shown in Table XI in the online-only Data Supplement. No significant associations with stroke subphenotypes were found after correction for multiple hypothesis testing.
Discussion
The present study represents the largest effort to identify novel gene loci regulating plasma fibrinogen levels. Overall, we identified 24 independent genome-wide significant SNPs in 23 loci, including 15 loci with newly discovered fibrinogen associations. Using our genetic findings, we found no evidence for a causal role of fibrinogen in CAD, stroke, and VTE.
The proportion of variance in plasma fibrinogen level accounted for by all 24 fibrinogen-associated lead SNPs increased to 3.7% (a detailed description of the novel nearby candidate genes is presented in Table V in the online-only Data Supplement). These results support the notion that regulation of plasma fibrinogen levels is driven by multiple genes, each having a modest effect on the phenotype. It is likely that even more loci with smaller effects remain to be discovered.
Relevance of the Fibrinogen-Related Loci in Non-European-Ancestry Individuals
We performed the first meta-analysis of GWA studies on black samples, and we provide evidence for a significant association of a weighted SNP score based on the 24 lead SNPs from the European-ancestry meta-analysis with levels of fibrinogen in both blacks (P=1.5×10 −8 ) and Hispanics (P=3.8×10 −15 ). Thus, despite differences in allele frequencies or differences in the relative impact of covariates associated with fibrinogen among populations, loci identified in European-ancestry samples collectively contribute to the regulation of plasma fibrinogen in black and Hispanic populations. Twenty of 24 lead SNPs showed the same direction of effect when the European sample was compared with either the black or the Hispanic sample. The substantially smaller size of the black and Hispanic cohorts compared with the total sample with European ancestry restricted available power and may have limited the significance of the candidate SNP associations in these populations (see Power Calculations in the Methods section of the online-only Data Supplement).
Pathways Involved in Regulation of Plasma Fibrinogen Level
It is interesting to note that several of the genome-wide significant loci identified in the present study harbor inflammatory genes, a remarkable set of which relate to the interleukin-1 pathway, indicating the importance of this pathway in the regulation of fibrinogen. Most of these inflammatory genes have previously been reported in relation to other inflammation-related phenotypes and diseases. For example, IL6R, NLRP3, IL1RN/ILF10, and IRF1 were recently identified in a GWA study meta-analysis of C-reactive protein conducted on European samples. 32 Both fibrinogen and C-reactive protein are acute-phase proteins with levels that are largely influenced by inflammatory triggers. It is thus not surprising that they are both partly regulated by a common group of genes that are implicated in the immune response. These results are also consistent with our in silico gene-set enrichment analyses, which showed that inflammation-related pathways, including acute-phase response and interleukin signaling, were most enriched for fibrinogen-associated genes. In this regard, interesting new plausible candidate genes could be discerned within the newly identified loci, including IL6, located in the TOMM7-IL6 locus on chromosome 7, and IL1R1, located in the cytokine receptor gene cluster on chromosome 2.
Our gene-set enrichment analysis also highlighted genes regulating fat metabolism as important in the control of plasma fibrinogen concentration, as indicated by the strong representation of adipocytokine signaling genes. This is consistent with our observation that smoking and body mass index contributed ≈5.3% of the plasma fibrinogen variation and with data from the Fibrinogen Studies Collaboration, reporting that 7% of the variation in plasma fibrinogen concentration was accounted for by smoking, body mass index, and high-density lipoprotein cholesterol. 33
Relations to Cardiovascular Disease
Although plasma fibrinogen concentration has been identified as a predictor of incident CAD events, 1, 34 it has been argued that increased plasma fibrinogen levels in population subgroups at increased CAD risk could be attributable to other mechanisms, including existing atherosclerosis, which might induce a proinflammatory state with a subsequent increase in acute-phase reactants such as fibrinogen or C-reactive protein. Given the associations of fibrinogen levels with other established CAD risk factors (eg, smoking and body mass index), it remains uncertain whether these other factors may confound the association of fibrinogen with disease risk. Prior studies that assessed the causality of the association between plasma fibrinogen concentration and risk of CAD by mendelian randomization using 2 common SNPs located in the promoter region of the FGB gene found no significant association of this locus with CAD, concluding that the relationship was noncausal. 35, 36 One limitation of these studies is that this single locus might have biologically unusual effects on measured fibrinogen levels. 35, 36 Our analysis of 23 other fibrinogen-associated SNPs offers a broader perspective and thus a more robust and generalizable evaluation of the causal relationship between fibrinogen and cardiovascular events. A further strength of our study is that we present estimates of the effects on risk of clinical outcomes individually for each SNP and globally for all SNPs combined.
Our results do not support a causal relationship between plasma fibrinogen level and CAD. In fact, consistent with the negative results from previous mendelian randomization, the lead SNP located in the FGB gene showed no association with CAD. Whereas SNPs rs4129267, rs6734238, and rs1154988, located in the IL6R, IL1F10/IL1RN, and PCCB loci, respectively, were significantly associated with CAD in CARDIoGRAM and C4D, the direction of effect was consistent only for the SNP located in the IL6R locus (ie, the allele that lowered the plasma fibrinogen concentration also lowered CAD risk). Furthermore, the global effect of all 24 fibrinogen-associated SNPs was not associated with CAD risk (odds ratio, 1.00; 95% confidence interval, 0.97-1.03).
Overall, our results suggest that systemic inflammation both causes raised fibrinogen level and (by a different mechanism) is associated with increased risk of CAD. The lack of overlap between the top CAD-associated SNPs from the literature and the fibrinogen-associated SNPs identified in our study further argues against a reverse causality hypothesis in which inflammation caused by the atherosclerosis process would raise the fibrinogen level.
Although not as consistent as for CAD or myocardial infarction, some studies have also suggested that an elevated fibrinogen concentration is a risk factor for stroke. 3, [37] [38] [39] In the present study, none of the fibrinogen-associated SNPs were significantly associated with stroke. Our findings suggest that similar to what we observed for CAD, a raised fibrinogen concentration is not causally related to stroke, although a positive trend was observed that warrants further investigation. Similarly, our results show that none of the fibrinogen-associated SNPs were significantly associated with VTE after correction for multiple testing, although rs1800789G in the fibrinogen gene cluster, which is associated with higher fibrinogen level in our discovery study, showed a clear trend (P=0.004). However, given the small sample size of the VTE cases examined, the power for detection of VTE association in our data is substantially lower than for stroke and CAD (see Methods in the onlineonly Data Supplement). 
Conclusions
The present meta-analysis of fibrinogen GWA studies, based on a 4-fold greater sample size than previous meta-analyses (≈91 500 individuals), identified 24 independent signals in 23 loci (of which 15 are new) and increased the proportion of variance of plasma fibrinogen level accounted for by all lead SNPs in genome-wide significant loci from <2% to 3.7%. For some of these loci, our pathway and eQTL analyses provided supporting evidence on the most plausible candidate genes. Finally, our study does not support causal involvement of fibrinogen in cardiovascular disease, particularly in clinically apparent CAD. Functional studies are needed to confirm and to characterize candidate genes suggested by the in silico analyses presented here. Future studies aimed at explaining the substantial missing heritability of plasma fibrinogen concentration should focus on exploring gene-gene and gene-environment interactions and on applying resequencing technologies to elucidate the role of rare variants. ; Dr Seshadri). The WGHS is supported by HL043851 and HL080467 from the NHLBI and CA047988 from the National Cancer Institute, the Donald W. Reynolds Foundation, and the Fondation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen. The SardiNIA (''Progenia'') team was supported by contract NO1-AG-1-2109 from the NIA. We thank the many individuals who generously participated in this study, the mayors and citizens of the Sardinian towns involved, the head of the Public Health Unit ASL4, and the province of Ogliastra for their volunteerism and cooperation. In addition, we are grateful to the mayor and the administration in Lanusei for providing and furnishing the clinic site. 
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